Transfusion guidelines

All products are leukoreduced and CMV safe.

Packed red blood cells

  • Hct <24% in non-bleeding patient.
  • Hct <30% and symptomatic anemia (e.g. tachycardia, tachypnea, etc.) or at risk for ischemia.
  • Symptomatic chronic anemia or treatment of life threatening conditions in sickle cell disease.

Platelets

  • Platelet count <10,000 – 20,000 in non-bleeding patient.
  • Platelet count <50,000 with impending surgery or invasive procedure.
  • Platelet count <100,000 with trauma or major surgery with bleeding, or anticipated CNS and/or ocular bleeding.
  • Bleeding or anticipated surgery in patients with qualitative platelet defect or patients on antithrombotic agents.
  • Diffuse microvascular bleeding following cardiopulmonary bypass, regardless of platelet count.
  • Diffuse microvascular bleeding, platelet count not yet available.

Frozen plasma

  • PT/INR > 1.5 and active bleeding, or anticipated major surgery or invasive procedure.
  • Urgent reversal of warfarin therapy.
  • Intracranial bleeding and PT/INR > 1.3.
  • Diffuse microvascular bleeding and PT and PTT studies are not yet available.
  • ATIII (if ATIII concentrate is not available), Protein C, or Protein S deficiency.
  • PT/INR > 1.2 with regional anesthesia procedure including epidural removal.

Cryoprecipitate

  • Fibrinogen level <100 mg/dl with active bleeding or anticipated surgery or invasive procedure.
  • Von Willebrand’s disease or hemophilia unresponsive to DDAVP and no appropriate factor concentrate available.
  • Factor XIII deficiency.
  • Dysfibrinogenemia.

Irradiated blood components

  • Patients with leukemia, non-Hodgkin’s lymphoma, neuroblastoma or glioblastoma who are undergoing intensive chemotherapy and any other patients undergoing intensive chemotherapy or immunosuppressive therapy.
  • Hodgkin’s disease, acute leukemia.
  • Bone marrow transplant patients.
  • Chronic lymphocytic leukemia patients treated with fludarabine.
  • Recipients of HLA or platelet crossmatched components.
  • Patients receiving blood from blood relatives.
  • Patients with lymphopenia (absolute lymphocyte count <500/ml) and bone marrow suppression.
  • Intrauterine transfusion for fetuses.
  • Postnatal exchange transfusion.
  • Premature infants.

Contact us

Salem Health Laboratories can be reached at 503-814-5227 (LABS).

Client Services

503-814-5227 (LABS)